27-Mar-2026
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza at ATTD 2026
Globe Newswire (Mon, 9-Mar 9:05 AM ET)
MannKind Announces Settlement of Convertible Senior Notes
Globe Newswire (Thu, 5-Mar 4:30 PM ET)
MannKind to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 4-Mar 9:00 AM ET)
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Globe Newswire (Thu, 26-Feb 8:00 AM ET)
MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Globe Newswire (Thu, 19-Feb 9:00 AM ET)
MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Globe Newswire (Wed, 18-Feb 9:00 AM ET)
Globe Newswire (Mon, 9-Feb 6:05 AM ET)
Market Chameleon (Mon, 26-Jan 3:38 AM ET)
Globe Newswire (Mon, 26-Jan 6:05 AM ET)
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
Globe Newswire (Fri, 23-Jan 12:56 PM ET)
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Mannkind trades on the NASDAQ stock market under the symbol MNKD.
As of March 27, 2026, MNKD stock price declined to $2.28 with 5,301,157 million shares trading.
MNKD has a beta of 1.21, meaning it tends to be more sensitive to market movements. MNKD has a correlation of 0.07 to the broad based SPY ETF.
MNKD has a market cap of $692.19 million. This is considered a Small Cap stock.
Last quarter Mannkind reported $112 million in Revenue and $.01 earnings per share. This beat revenue expectation by $13 million and met earnings estimates .
In the last 3 years, MNKD traded as high as $7.63 and as low as $2.23.
The top ETF exchange traded funds that MNKD belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
MNKD has underperformed the market in the last year with a price return of -55.3% while the SPY ETF gained +13.1%. MNKD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -60.6% and -17.7%, respectively, while the SPY returned -7.9% and -4.0%, respectively.
MNKD support price is $2.20 and resistance is $2.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MNKD shares will trade within this expected range on the day.